S
Stefan Faderl
Researcher at University of Texas MD Anderson Cancer Center
Publications - 586
Citations - 36426
Stefan Faderl is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 96, co-authored 577 publications receiving 34155 citations. Previous affiliations of Stefan Faderl include Penn State Milton S. Hershey Medical Center & Hackensack University Medical Center.
Papers
More filters
Journal ArticleDOI
Final Report of a Phase II Study of 5-Azacitidine and Vorinostat in Patients (pts) with Newly Diagnosed Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML) Not Eligible for Clinical Trials Because Poor Performance and Presence of Other Comorbidities
Guillermo Garcia-Manero,Elihu H. Estey,Elias Jabbour,Gautam Borthakur,Tapan M. Kadia,Kiran Naqvi,Ross L. Levine,Zeev Estrov,Alfonso Quintás-Cardama,Marina Konopleva,Stefan Faderl,Maria Tanaka,Hui Yang,Farhad Ravandi,William G. Wierda,Jorge E. Cortes,Patricia Ann Boone,Hagop M. Kantarjian +17 more
TL;DR: A phase II of the combination of 5-azacitidine and the histone deacetylase inhibitor vorinostat was conducted to study the impact of therapy in patients not eligible for clinical trials, and treatment was well tolerated.
Journal ArticleDOI
N-(4-Hydroxylphenyl)retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL).
TL;DR: The data show that 4-HPR is a potent inhibitor of ALL cell proliferation and that it induces in vitro apoptotic cell death in ALL blasts.
Journal ArticleDOI
FCR-3 as Frontline Therapy for Patients with Chronic Lymphocytic Leukemia (CLL).
Susan O'Brien,William G. Wierda,Stefan Faderl,Alessandra Ferrajoli,Carlos E. Bueso-Ramos,Mary L. Browning,Hagop M. Kantarjian,Michael J. Keating +7 more
TL;DR: The addition of 3 doses of Rituximab to FC chemotherapy does not appear to provide greater benefit than one dose, and no patient has progressed with a median follow-up of 10 months.
Journal ArticleDOI
Phase II Study of the JAK2 Inhibitor, INCB018424, In Patients with Refractory Leukemias Including Post-Myeloproliferative Disorder (MPD) Acute Myeloid Leukemia (sAML)
Alireza Eghtedar,Srdan Verstovsek,Jorge E. Cortes,Zeev Estrov,Jan A. Burger,Carol Bivins,Stefan Faderl,Alessandra Ferrajoli,Gautam Borthakur,Solly George,Robert C. Newton,Hagop M. Kantarjian,Farhad Ravandi +12 more
TL;DR: INCB018424 is well-tolerated and has activity particularly in pts with sAML and CMML but also in AML and MDS, with or without JAK2 V617F mutation, which is clearly demonstrated in myeloproliferative disorders.
Journal ArticleDOI
Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia.
Masamitsu Yanada,Gautam Borthakur,Guillermo Garcia-Manero,Farhad Ravandi,Stefan Faderl,Sherry Pierce,Hagop M. Kantarjian,Elihu H. Estey +7 more
TL;DR: It is suggested that blood counts at CR, information readily available, are useful in prognostication in AML and independently predictive of longer RFS in the validation set.